Turn Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates significantly across the bottom line: GAAP EPS was -$0.20 vs. -$0.02 expected, primarily driven by substantial non-cash derivative losses. While revenue remained at zero in-line with expectations for a clinical-stage firm, R&D expenses rose to $0.5M reflecting accelerated Phase 2 GX-03 enrollment. Management extended the cash runway into Q3 2027 following positive interim Phase 2 data and the expansion of the study population.